Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis

Inclusion Criteria: * Patients must be able to understand and communicate with the investigator and comply with the requirements for the study and must give a written, signed, and dated informed consent before any study assessment is performed * Patient is currently enrolled in CAIN457A2208 or has completed the core and extension study treatment periods in the ongoing AIN457 phase III clinical trial Studies (e.g., CAIN457C2301 and CAIN457C2301E1) * Willingness to discontinue AIN457 or be weaned from standard of care immunosuppressive therapy if recommended by the study investigator Exclusion Criteria: * Need for treatment with ocular procedures or systemic medications prohibited in this study including an alkylating agent or another biologic therapy other than AIN457 * Pregnant or nursing (lactating) women * Women of childbearing potential unwilling to use protocol defined acceptable methods of contraception throughout the study and for 16 weeks after study drug discontinuation Other protocol-defined inclusion/exclusion criteria may apply